Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

A. Amro, Kanaan Mansoor, M. Amro, A. Sobeih, Obadah Aqtash, H. Hirzallah, Alaa Gabi, M. Urella, W. Ahmed, Sandra Shenouda, R. Sayyed
{"title":"Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study","authors":"A. Amro, Kanaan Mansoor, M. Amro, A. Sobeih, Obadah Aqtash, H. Hirzallah, Alaa Gabi, M. Urella, W. Ahmed, Sandra Shenouda, R. Sayyed","doi":"10.33470/2379-9536.1220","DOIUrl":null,"url":null,"abstract":"Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with acute coronary syndrome who undergo percutaneous coronary intervention. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.","PeriodicalId":93035,"journal":{"name":"Marshall journal of medicine","volume":"42 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marshall journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33470/2379-9536.1220","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with acute coronary syndrome who undergo percutaneous coronary intervention. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
普拉格雷在经皮冠状动脉介入治疗(PCI)后患者中的不当使用。单中心研究
Prasugrel是一种噻吩吡啶,已被美国食品和药物管理局(fda)批准与阿司匹林联合使用,用于减少急性冠状动脉综合征患者经皮冠状动脉介入治疗后的血栓形成事件和支架血栓形成。本回顾性研究旨在评估普拉格雷不当使用的频率,并强调普拉格雷仍然需要更多的关注,因为不当使用可能导致显著的发病率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
8 weeks
期刊最新文献
Management of Cryptogenic Stroke secondary to large ASD with percutaneous Occluder Device and Antiplatelet drugs. Ogilvie's Syndrome: Acute Colonic Pseudoobstruction. A Review for Residents. Overcoming Communication Challenges: Training Family Medicine Interns Amidst COVID-19 A Case of Occlusive Myocardial Infarction Caused by Nephrotic Syndrome in a 26-Year-Old Type 1 Diabetic More Physicians Alone Won’t Solve Rural America’s Health Care Problems
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1